However, anti-PD-1/PD-L1 therapy is considered ineffective in most patients with CRC, and only those with MMR-d tumors and a high tumor mutational burden (TMB) have been found to be responsive to anti-PD-1/PD-L1 therapy6-9. Here, CD274 is linked to neoplasm.